OpGen

OpGen EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OpGen (OPGN) as of Oct 19, 2026 is 24.03 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 399,855.00 USD — a change of 5,909.20% (higher).

EBITDA

24.03 MUSD

YoY

5,909.20%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OpGen is 2025 24.03 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OpGen was 2024 399,855.00 USD. It decreases by 5,909.20% higher compared to the previous year.

The OpGen EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA
Date
EBITDA
Jan 1, 2018
-13.18 M USD
Jan 1, 2019
-12.27 M USD
Jan 1, 2020
-21.50 M USD
Jan 1, 2021
-23.27 M USD
Jan 1, 2022
-22.22 M USD
Jan 1, 2023
-15.69 M USD
Jan 1, 2024
399,855.00 USD
Jan 1, 2025
24.03 M USD
The OpGen EBITDA history
YEAREBITDAYoY
24.03 MUSD+5,909.20%
399,855.00USD-102.55%
-15.69 MUSD-29.39%
-22.22 MUSD-4.53%
-23.27 MUSD+8.27%
-21.50 MUSD+75.17%
-12.27 MUSD-6.90%
-13.18 MUSD-13.51%
-15.24 MUSD-19.83%
-19.01 MUSD+30.80%
-14.53 MUSD+161.15%
-5.57 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

OpGen Stock analysis

What does OpGen do? OpGen Inc is a biotechnology company based in Gaithersburg, Maryland, operating within the Health Care sector. The company went public on May 5, 2015, with ticker OPGN and ISIN US68373L5057. It currently employs three people. OpGen develops molecular information solutions focused on combating infectious diseases in global healthcare settings. The company's technology involves DNA tests and bioinformatics to address antibiotic resistance, assisting healthcare providers in managing patient care decisions and monitoring the spread of multidrug-resistant microorganisms. Its solutions aim to guide clinicians with information about life-threatening infections and help manage patient outcomes. The company's website is http://opgen.com/. OpGen is engaged in creating tools to help protect the hospital biome through customized screening and surveillance. The firm markets its high-resolution DNA tests under the Acuitas trade name. The company has a global network of customers and partners. OpGen does not provide specific details on its product names beyond Acuitas, and no additional financial figures or historical data are available in the provided information. OpGen is one of the most popular companies on Eulerpool.

Frequently Asked Questions about OpGen stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OpGen is 24.03 M USD in 2025.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of OpGen changed from 399,855.00 USD to 24.03 M USD, representing a 5,909.20% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) OpGen since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s OpGen historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Income Statement — OpGen

RevenueGross ProfitEBITEBITDANet IncomeEPSCost of Goods SoldR&D ExpensesSG&A ExpensesOperating ExpensesInterest ExpensePretax IncomeTax ExpenseDepreciation & AmortizationRevenue per ShareEBIT per ShareDiluted EPSEBITDA per ShareOther Income/Expense

All Key Metrics — OpGen